Stock Market Impact: Abivax’s Paris‑listed shares plunged more than 32% in early European trading (by 07:34 GMT) following the release of late‑stage ulcerative colitis trial results.
Listed Companies and Sectors: The data pertain to Abivax, a biotech/pharma company, and its oral drug obefazimod targeting ulcerative colitis, impacting the Pharma / Healthcare sector.
Trial Results: In a 44‑week study, clinical remission was achieved by 50.8% of patients on the 25 mg dose and 51.3% on the 50 mg dose, compared with 10.4% on placebo, exceeding expectations and outperforming existing therapies.
Safety Concerns: The report highlighted a handful of rare malignancy events, deemed unrelated to the drug but introducing uncertainty; analysts described this as a potential labeling overhang rather than a clear causal safety risk.
Analyst Commentary: Stifel analysts, led by Damien Choplain, noted the malignancy signal could not be ignored but viewed it as a labeling issue, which contributed to the share‑price pressure.
